Pharmaceutical News and Articles

Dust Yields Clues to Viral Outbreaks, Study Finds

TUESDAY, May 26, 2026 Dusting just took on a whole new purpose Scientists say dust contains clues to viruses circulating in offices, schools and other buildings

Many U.S. College Students With Psychosis Are Not Receiving Treatment

TUESDAY, May 26, 2026 The college years are prime time for the emergence of mental illnesses involving psychosis, according to a new study.However, almost 60 of

Yoga Eases Insomnia And Anxiety In Cancer Survivors, Study Finds

TUESDAY, May 26, 2026 Sleepless nights, anxiety, mood swings and fatigue are all potential issues for cancer survivors. Now, research finds the ancient art of y

Everyone Has A Family Doc, But Can You Get An Appointment?

Welcome to the first installment in HealthDay s exclusive investigative series, Is There A Doctor In The House The U.S. Family Medicine Crisis. Through original

Antibiotics Won't Help Ease Asthma-Linked Wheezing in Kids

TUESDAY, May 26, 2026 Kids with asthma can have wheezing attacks severe enough to trigger a visit to the ER. However, a new trial shows that getting antibiotics

A Single Dose of Lilly's PCSK9 Base Editor, VERVE-102, Reduced PCSK9 by up to 88% and LDL-C by up to 62%, with Durable Effects Supporting its Potential as a One-Time Treatment for Hypercholesterolemia

Eli Lilly and Company (NYSE LLY) today announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine designe

Datroway Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

FDA Approves Differin Epiduo Acne Gel (adapalene/benzoyl peroxide) for Nonprescription Use in the Treatment of Acne

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

Biogen Inc. (Nasdaq BIIB) and Denali Therapeutics Inc. (Nasdaq DNLI) today announced topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151), a

Foundayo (orforglipron) was Associated with Reduced Body Weight of Up To 13% in Adults 65 and Older with Obesity or Overweight, in New Analysis of ATTAIN-1/2

INDIANAPOLIS, May 22, 2026 Eli Lilly and Company (NYSE LLY) announced a new analysis from the Phase 3 ATTAIN-1 and ATTAIN-2 trials showing that Foundayo (orforg